Orchid Chemicals And Pharmaceuticals
Orchid Chemicals and Pharmaceuticals Ltd., commonly referred to as Orchid Pharma, is a prominent player in the Indian pharmaceutical industry, headquartered in Chennai, India. Founded in 1992, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms, particularly in the areas of anti-infectives, cardiovascular, and central nervous system medications. With a strong presence in both domestic and international markets, Orchid Pharma has achieved significant milestones, including regulatory approvals from major global health authorities. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic segments. Orchid's strategic focus on research and development has positioned it as a competitive force in the pharmaceutical landscape, making it a trusted partner for healthcare providers worldwide.
DitchCarbon Score
How does Orchid Chemicals And Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Orchid Chemicals And Pharmaceuticals's score of 24 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Orchid Chemicals And Pharmaceuticals's reported carbon emissions
In 2023, Orchid Chemicals and Pharmaceuticals reported significant carbon emissions, totalling approximately 385,968,000 kg CO2e. This figure comprises about 4,594,000 kg CO2e from Scope 1 emissions and approximately 381,028,000 kg CO2e from Scope 2 emissions. The company has committed to achieving net-zero emissions across all scopes by 2050, with interim targets set through the Science Based Targets initiative (SBTi). In 2024, emissions decreased to about 41,557,479 kg CO2e, with Scope 1 emissions at approximately 339,939 kg CO2e. This reduction reflects the company's ongoing efforts to lower its carbon footprint while maintaining a revenue of about USD 98,341,571. Orchid Pharma's commitment to sustainability is evident in its long-term strategy, aiming for substantial reductions in greenhouse gas emissions as part of its corporate responsibility in the pharmaceuticals sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 4,594,000 | 000,000.00 |
| Scope 2 | 381,028,000 | 00,000,000.00 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orchid Chemicals And Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
